IDEAYA Biosciences clinical trials
IDEAYA Biosciences is the lead sponsor of 14 current clinical trials in our USA, Canada, Australia, Germany, France, Spain, Italy, Netherlands, UK, Belgium, Poland, Switzerland, Israel, Denmark, Austria, Czechia, South Korea, Taiwan, Egypt and EU (CTIS) registers. 7 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Darovasertib, Crizotinib and Durvalumab. The most-studied condition is Uveal Melanoma.
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by IDEAYA Biosciences
11 on ClinicalTrials.govRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
IDEAYA Biosciences in the EU trials register (CTIS)
3 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System with IDEAYA Biosciences as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Countries |
|---|---|---|---|
|
A study of IDE892 as monotherapy and combination in MTAP-deleted Advanced Solid Tumors
2025-524715-37-00 · Diagnosis
|
Phase 1 | Authorised | Spain, France |
|
An Open-Label Study of IDE034 in Adult Participants with Locally
Advanced/Metastatic Solid Tumors
2026-526299-21-00 · Female Urogenital Diseases and Pregnancy Complications
|
Phase 1 | Ongoing | Spain |
|
A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer
2025-523438-24-00 · Neoplasms
Drug: Durvalumab |
Phase 1 | Authorised | France, Spain |
Drugs in IDEAYA Biosciences trials
15 compoundsDrugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
Conditions in IDEAYA Biosciences trials
21 conditionsBy trial register
A trial with sites in more than one country appears in each of those registers.
Other sponsors in Uveal Melanoma
| Sponsor | Trials |
|---|---|
| Aura Biosciences | 2 |
| Inge Marie Svane | 1 |
Sponsors with the most current trials registered for this condition.
Questions about IDEAYA Biosciences trials
How many clinical trials does IDEAYA Biosciences sponsor?
IDEAYA Biosciences is the lead sponsor of 11 current trials on ClinicalTrials.gov in our USA, Canada, Australia, Germany, France, Spain, Italy, Netherlands, UK, Belgium, Poland, Switzerland, Israel, Denmark, Austria, Czechia, South Korea, Taiwan and Egypt registers, and 3 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are IDEAYA Biosciences trials recruiting?
Yes. 7 of its 11 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Which drugs is IDEAYA Biosciences testing?
Its current trials name 15 drugs and biologicals as interventions. The most frequent are Darovasertib (5), Crizotinib (3), Durvalumab (2), IDE397 (2) and Keytruda (2). The number in brackets is how many of its trials name each drug.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.